<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31642025</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1950</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>79</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drugs</Title>
          <ISOAbbreviation>Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Upadacitinib: First Approval.</ArticleTitle>
        <Pagination>
          <StartPage>1819</StartPage>
          <EndPage>1828</EndPage>
          <MedlinePgn>1819-1828</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-019-01211-z</ELocationID>
        <Abstract>
          <AbstractText>Upadacitinib (Rinvoqâ„¢), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Duggan</LastName>
            <ForeName>Sean</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Keam</LastName>
            <ForeName>Susan J</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drugs</MedlineTA>
        <NlmUniqueID>7600076</NlmUniqueID>
        <ISSNLinking>0012-6667</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C507904">JAK1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053613">Janus Kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053613" MajorTopicYN="N">Janus Kinase 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31642025</ArticleId>
        <ArticleId IdType="doi">10.1007/s40265-019-01211-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s40265-019-01211-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>J Clin Pharmacol. 2019 Jun;59(6):856-862</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30633369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2018 Jun 23;391(10139):2503-2512</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2018 Jun 23;391(10139):2513-2524</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthritis Rheumatol. 2016 Dec;68(12):2857-2866</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27390150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthritis Rheumatol. 2019 Nov;71(11):1788-1800</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31287230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 2017 Oct;83(10):2242-2248</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28503781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Drug Dev. 2019 Feb;8(2):208-216</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29688617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMC Rheumatol. 2018 Aug 28;2:23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30886973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2018 Aug;57(8):977-988</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29076110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2019 Sep;59(9):1188-1194</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30973649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 2018 May;103(5):836-842</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28762476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2020 Jan;60(1):86-95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31378969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Rheum Dis. 2019 Nov;78(11):1454-1462</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31362993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthritis Rheumatol. 2016 Dec;68(12):2867-2877</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27389975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2016 Dec;55(12):1547-1558</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27272171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2019 Jun 8;393(10188):2303-2311</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31130260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2019 Aug;58(8):1045-1058</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30945116</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
